| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
RAPT Therapeutics, Inc.
13D/A
RAPT · 75382E109
|
4.9% |
12/23/2024
Event 12/23/2024
|
||||
| The Column Group II, LP | 0.6% | |||||
| The Column Group II GP, LP | 0.6% | |||||
| Ponoi Capital, LP | 0.4% | |||||
| Ponoi Management, LLC | 0.4% | |||||
| Ponoi Capital II, LP | 0.5% | |||||
| Ponoi II Management, LLC | 0.5% | |||||
| The Column Group IV, LP | 3.9% | |||||
| The Column Group IV-A, LP | 0.1% | |||||
| The Column Group IV GP, LP | 4.0% | |||||
| The Column Group, LLC | 0% | |||||
| Peter Svennilson | 4.9% | |||||
| David V. Goeddel | 4.9% | |||||
| Tim Kutzkey | 4.8% | |||||
| Schedule 13G · 1 security · passive | ||||||
|
ORIC Pharmaceuticals, Inc.
13G/A
ORIC · 68622P109
|
3.7% |
11/17/2025
Event 9/30/2025
|
||||
| The Column Group II, LP | 3.6% | |||||
| The Column Group II GP, LP | 3.6% | |||||
| David V Goeddel | 3.7% | |||||
| Peter Svennilson | 3.7% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.